Avicenna Alliance: enhanced knowledge, improved decisions, better outcomes
FULL MENU

Pharma / CMC Task Force

Pharma / CMC Task Force

BACK

Pharma / CMC Task Force

Mission: Accelerate the adoption of in silico technologies in pharmaceutical development, Chemistry, Manufacturing and Controls (CMC), and regulatory decision-making throughout the product lifecycle.

In silico technologies offer significant opportunities to transform pharmaceutical development and manufacturing by improving efficiency, supporting product quality and safety, reducing development costs, and accelerating the delivery of new medicines to patients.

Across the pharmaceutical product lifecycle, computational approaches can support formulation development, process understanding, technology transfer, batch size definition, and the identification and management of Critical Quality Attributes (CQAs). They can also strengthen regulatory strategies by providing scientific evidence to support decision-making and by helping address the evolving needs of pharmaceutical regulators and other healthcare stakeholders.

However, broader adoption of in silico approaches requires greater confidence in their reliability, clearer regulatory pathways, and stronger collaboration between industry, academia, and competent authorities. As pharmaceutical regulatory frameworks and strategies continue to evolve, it is essential to ensure that digital and computational technologies are recognised as valuable tools for innovation and evidence generation.

The Pharma / CMC Task Force brings together expertise from academia and industry to advance the understanding, acceptance, and practical implementation of in silico technologies in pharmaceutical development and manufacturing. It acts as a centre of expertise, supporting dialogue with regulatory authorities and healthcare stakeholders, identifying opportunities for implementation, and promoting approaches that can facilitate the integration of computational methods into pharmaceutical practice and regulatory submissions.

Goals

  • Build a multidisciplinary expert community among Avicenna Alliance members, bringing together expertise in pharmaceutical sciences, CMC, computational modelling, industry, and regulatory affairs.
  • Identify and promote relevant in silico applications across pharmaceutical development, manufacturing, and the broader product lifecycle, including formulation development, technology transfer, process understanding, and product quality assessment.
  • Support regulatory acceptance of in silico approaches in pharmaceuticals by addressing regulatory requirements, identifying gaps, and developing recommendations for their use in evidence generation and regulatory submissions.
  • Provide guidance on CMC applications, including the generation and use of in silico data to support discussions with regulatory authorities on batch size, Critical Quality Attributes (CQAs), and related development strategies.
  • Engage with regulatory authorities and healthcare stakeholders to inform evolving pharmaceutical strategies and promote the integration of digital and computational technologies into regulatory activities.
  • Build confidence in industry and other stakeholders by sharing knowledge, identifying good practices, and promoting scientifically sound approaches to the application of in silico technologies.
  • Identify opportunities for targeted applications of in silico medicine in specific therapeutic indications and patient populations, supporting pharmaceutical innovation and the development of new medicines.



Ani Amar

Ani Amar

Co-chair of CMC Application TF

Postdoctoral fellow, Computational modeling of the heart at ELEM Biotech

READ BIO
Himanshu Kaul

Himanshu Kaul

Co-chair of CMC Application TF

Royal Academy of Engineering Research Fellow University of Leicester

READ BIO
Yu Feng

Yu Feng

Co-Chair of the Pharmaceutical Strategy (Pharma) Task Force

Associate Professor Oklahoma State University

READ BIO

NEWS

News ADVANCING THE VIRTUAL HUMAN TWIN ECOSYSTEM - Avicenna Alliance at VHT Net Initiative Meeting

ADVANCING THE VIRTUAL HUMAN TWIN ECOSYSTEM - Avicenna Alliance at VHT Net Initiative Meeting

On 20 October, Avicenna Alliance was represented by many members and partners, including our President and Secretary General, Thierry Marchal, at the annual VHT Net initiative meeting, organised by the VPH - The Society for In Silico Medicine at the European Commission.

News SILICA General Assembly - Strengthening collaboration on AI, synthetic data and in silico methods in healthcare

SILICA General Assembly - Strengthening collaboration on AI, synthetic data and in silico methods in healthcare

The Avicenna Alliance is pleased to support initiatives that bring stakeholders together to advance the use of artificial intelligence, synthetic data, and computational modelling and simulation in healthcare.

News Avicenna Days (AAD) 2027

Avicenna Days (AAD) 2027

Three days. One journey. From research to real-world impact.

Sign up for our monthly newsletter!

Sign up for our monthly newsletter!

Fill in the fields you find below

Avicenna Alliance is an initiative of:

Avicenna VPH

© 2018-2026 Avicenna Alliance | powered by We Berry